{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:14:53Z","timestamp":1791389693810,"version":"4.3.3"},"reference-count":105,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T00:00:00Z","timestamp":1675555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Herpes simplex virus (HSV) and varicella zoster virus (VZV) are alpha herpesviruses that establish life-long latent infection in neuronal ganglia after primary infection. Periodic reactivation of these viruses results in recurrent infections that can have significant impact on patients\u2019 quality of life. HSV commonly causes oral and genital mucocutaneous infections whereas VZV is responsible for varicella\/chickenpox and herpes zoster\/shingles, but cancer patients are at particularly higher risk of complications including disseminated and visceral infections due to impaired cell-mediated immunity. While diagnosis of more common HSV and\/or VZV infections is frequently clinically based, immunocompromised hosts may have atypical skin presentation or visceral involvement. Thus, diagnostic confirmation using virus-specific tests such as polymerase chain reaction or immunohistochemical staining is crucial in some cases. Oral acyclovir, valacyclovir and famciclovir are usually used for mild to moderate infections and intravenous acyclovir is the drug of choice for severe or disseminated infections. Foscarnet can be used when acyclovir-resistance is confirmed or suspected. Pharmaceutical prophylaxis against HSV and\/or VZV should be considered in high-risk cancers patients. Currently, there is no commercially available vaccine against HSV, but VZV vaccines are available to prevent varicella and zoster.<\/jats:p>","DOI":"10.3390\/v15020439","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T04:08:07Z","timestamp":1675656487000},"page":"439","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Herpes Simplex Virus and Varicella Zoster Virus Infections in Cancer Patients"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5354-0209","authenticated-orcid":false,"given":"Ralph","family":"Tayyar","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,5]]},"reference":[{"key":"ref_1","unstructured":"Krug, L.T., and Pellett, P.E. (2022). Fields Virology, Wolters Kluwer. [7th ed.]. Available online: https:\/\/internalmedicine.lwwhealthlibrary.com\/content.aspx?sectionid=253047475&bookid=3210."},{"key":"ref_2","unstructured":"Schiffer, J.T., and Corey, L. (2019). Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases, Elsevier. [9th ed.]."},{"key":"ref_3","unstructured":"Whitley, R.J. (2019). Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases, Elsevier. [9th ed.]."},{"key":"ref_4","unstructured":"Dadwal, S.S., and Ito, J.I. (2015). Thomas\u2019 Hematopoietic Cell Transplantation, John Wiley & Sons, Ltd.. Available online: http:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/9781118416426.ch88."},{"key":"ref_5","unstructured":"Ho, D.Y., and Arvin, A.M. (2015). Thomas\u2019 Hematopoietic Cell Transplantation, John Wiley & Sons, Ltd.. Available online: http:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/9781118416426.ch89."},{"key":"ref_6","unstructured":"World Health Organization (WHO) (2021, July 20). Massive proportion of world\u2019s population are living with herpes infection. Available online: https:\/\/www.who.int\/news\/item\/01-05-2020-massive-proportion-world-population-living-with-herpes-infection."},{"key":"ref_7","unstructured":"Centers for Disease Control and Prevention (CDC) (2021, July 20). Products\u2014Data Briefs\u2014Number 304\u2014February 2018, Available online: https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db304.htm."},{"key":"ref_8","unstructured":"Knipe, D.M., Heldwein, E.E., Mohr, I.J., and Sodroski, C.N. (2022). Fields Virology, Wolters Kluwer. [7th ed.]. Available online: https:\/\/internalmedicine.lwwhealthlibrary.com\/content.aspx?sectionid=253047662&bookid=3210."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Looker, K.J., Magaret, A.S., May, M.T., Turner, K.M.E., Vickerman, P., Gottlieb, S.L., and Newman, L.M. (2015). Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140765"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/sti.2003.007823","article-title":"Oral shedding of herpes simplex virus type 2","volume":"80","author":"Wald","year":"2004","journal-title":"Sex. Transm. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1086\/505879","article-title":"Oral Herpes Simplex Virus Type 2 Reactivation in HIV-Positive and -Negative Men","volume":"194","author":"Kim","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3904\/kjim.2018.469","article-title":"Strong association between herpes simplex virus-1 and chemotherapy-induced oral mucositis in patients with hematologic malignancies","volume":"35","author":"Hong","year":"2020","journal-title":"Korean J. Intern. Med."},{"key":"ref_13","first-page":"571","article-title":"Human papilloma virus, herpes simplex virus and epstein barr virus in oral squamous cell carcinoma from eight different countries","volume":"32","author":"Jalouli","year":"2012","journal-title":"Anticancer. Res."},{"key":"ref_14","first-page":"1731","article-title":"Prevalence and association of human papillomavirus 16, Epstein-Barr virus, herpes simplex virus-1 and cytomegalovirus infection with human esophageal carcinoma: A case-control study","volume":"25","author":"Zhu","year":"2011","journal-title":"Oncol. Rep."},{"key":"ref_15","first-page":"1604","article-title":"Herpes Simplex Virus-2 as a Human Papillomavirus Cofactor in the Etiology of Invasive Cervical Cancer","volume":"94","author":"Smith","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-011-0609-2","article-title":"Herpes simplex encephalitis in patients with cancer","volume":"105","author":"Graber","year":"2011","journal-title":"J. Neuro-Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1542\/peds.2011-0017","article-title":"Varicella in Infants After Implementation of the US Varicella Vaccination Program","volume":"128","author":"Chaves","year":"2011","journal-title":"Pediatrics"},{"key":"ref_18","first-page":"1","article-title":"Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Marin","year":"2007","journal-title":"MMWR. Recomm. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/infdis\/jiq081","article-title":"Impact of 2-Dose Vaccination on Varicella Epidemiology: Connecticut\u20142005\u20132008","volume":"203","author":"Kattan","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_20","unstructured":"Centers for Disease Control and Prevention (CDC) (2021, July 20). Clinical Overview of Herpes Zoster (Shingles), Available online: https:\/\/www.cdc.gov\/shingles\/hcp\/clinical-overview.html."},{"key":"ref_21","unstructured":"Dooling, K.L. (2021, July 20). Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.MMWR Morb Mortal Wkly Rep, Available online: http:\/\/www.cdc.gov\/mmwr\/volumes\/67\/wr\/mm6703a5.htm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/320169","article-title":"Herpes zoster in older adults","volume":"32","author":"Schmader","year":"2001","journal-title":"Clin. Infect Dis. Off. Publ. Infect Dis. Soc. Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/infdis\/jiy625","article-title":"Risk of Herpes Zoster Prior to and Following Cancer Diagnosis and Treatment: A Population-Based Prospective Cohort Study","volume":"220","author":"Qian","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1055-9965.EPI-12-0815","article-title":"The Epidemiology of Herpes Zoster in Patients with Newly Diagnosed Cancer","volume":"22","author":"Habel","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_25","unstructured":"Arvin, A.M., and Abendroth, A. (2022). Fields Virology, Wolters Kluwer. [7th ed.]. Available online: https:\/\/internalmedicine.lwwhealthlibrary.com\/content.aspx?sectionid=253049036&bookid=3210."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1073\/pnas.85.8.2658","article-title":"Sequence analyses of herpesviral enzymes suggest an ancient origin for human sexual behavior","volume":"85","author":"Lowe","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rice, S.A. (2021). Release of HSV-1 Cell-Free Virions: Mechanisms, Regulation, and Likely Role in Human-Human Transmission. Viruses, 13.","DOI":"10.3390\/v13122395"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1016\/j.vaccine.2014.04.042","article-title":"Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer","volume":"32","author":"Bochennek","year":"2014","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0714.2008.00684.x","article-title":"Prevalence of oral herpes simplex virus reactivation in cancer patients: A comparison of different techniques of viral detection","volume":"38","author":"Djuric","year":"2008","journal-title":"J. Oral Pathol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e3187","DOI":"10.1097\/MD.0000000000003187","article-title":"Clinical Characteristics and Manifestation of Herpes Esophagitis: One Single-center Experience in Taiwan","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s10620-019-05493-x","article-title":"Variations in the Clinical Course of Patients with Herpes Simplex Virus Esophagitis Based on Immunocompetence and Presence of Underlying Esophageal Disease","volume":"64","author":"Hoversten","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.7326\/0003-4819-97-6-813","article-title":"Herpes simplex virus pneumonia: Clinical, virologic, and pathologic features in 20 patients","volume":"97","author":"Ramsey","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/cncr.24011","article-title":"Herpes simplex virus lower respiratory tract infection in patients with solid tumors","volume":"115","author":"Aisenberg","year":"2008","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200609-1322OC","article-title":"Herpes Simplex Virus Lung Infection in Patients Undergoing Prolonged Mechanical Ventilation","volume":"175","author":"Luyt","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1177\/0885066620965941","article-title":"Herpes Simplex Virus Type 1 Pneumonia\u2014A Review","volume":"36","author":"Jellinge","year":"2021","journal-title":"J. Intensiv. Care Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/clinids\/24.3.334","article-title":"Herpes Simplex Virus Hepatitis: Case Report and Review","volume":"24","author":"Kaufman","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s13365-021-01018-3","article-title":"Herpes simplex encephalitis in patients receiving chemotherapy and whole-brain radiation therapy","volume":"27","author":"Hersh","year":"2021","journal-title":"J Neurovirol."},{"key":"ref_38","unstructured":"Ho, D.Y., Enriquez, K., and Multani, A. (2020). Infectious Disease Clinics of North America, Elsevier. Available online: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552020300088."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1542\/peds.56.3.388","article-title":"Varicella in children with cancer: Seventy-seven cases","volume":"56","author":"Feldman","year":"1975","journal-title":"Pediatrics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/00365548.2014.901554","article-title":"Complications of herpes zoster in cancer patients","volume":"46","author":"Tran","year":"2014","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"842","DOI":"10.7326\/0003-4819-91-6-842","article-title":"Prolonged Herpes-Zoster Infection Associated with Immunosuppressive Therapy","volume":"91","author":"Gallagher","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.12688\/f1000research.7153.1","article-title":"Varicella Zoster Virus in the Nervous System","volume":"4","author":"Gilden","year":"2015","journal-title":"F1000Research"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3344\/kjp.2020.33.3.208","article-title":"Zoster sine herpete: A review","volume":"33","author":"Zhou","year":"2020","journal-title":"Korean J. Pain."},{"key":"ref_44","first-page":"243","article-title":"Neurological Disease Produced by Varicella Zoster","volume":"342","author":"Gilden","year":"2010","journal-title":"Virus React. Rash"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1348-0421.1997.tb01872.x","article-title":"Herpes simplex virus-specific IgM, IgA and IgG subclass antibody responses in primary and nonprimary genital herpes patients","volume":"41","author":"Hashido","year":"1997","journal-title":"Microbiol. Immunol."},{"key":"ref_46","first-page":"463","article-title":"Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection","volume":"12","author":"Morrow","year":"2006","journal-title":"Clin. Microbiol. Infect Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Andrei, G., and Snoeck, R. (2021). Advances and Perspectives in the Management of Varicella-Zoster Virus Infections. Molecules, 26.","DOI":"10.3390\/molecules26041132"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Sadowski, L., Upadhyay, R., Greeley, Z., and Margulies, B. (2021). Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2. Viruses, 13.","DOI":"10.3390\/v13071228"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1128\/AAC.39.12.2759","article-title":"Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans","volume":"39","author":"Seaber","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0002-9343(82)90097-3","article-title":"Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host","volume":"73","author":"Meyers","year":"1982","journal-title":"Am. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7326\/0003-4819-102-6-783","article-title":"Oral Acyclovir Therapy for Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Marrow Transplant Recipients","volume":"102","author":"Shepp","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1601-0825.2006.01202.x","article-title":"Oral and perioral herpes simplex virus type 1 (HSV-1) infection: Review of its management*","volume":"12","author":"Arduino","year":"2006","journal-title":"Oral Dis."},{"key":"ref_53","unstructured":"Aoki, F.Y. (2019). Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases, Elsevier. [9th ed.]."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/CMR.16.1.114-128.2003","article-title":"Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy","volume":"16","author":"Bacon","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1086\/315524","article-title":"Resistance to Antiviral Drugs in Herpes Simplex Virus Infections among Allogeneic Stem Cell Transplant Recipients: Risk Factors and Prognostic Significance","volume":"181","author":"Chakrabarti","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbmt.2010.06.020","article-title":"Treatment of Acyclovir-Resistant Herpes Simplex Virus with Continuous Infusion of High-Dose Acyclovir in Hematopoietic Cell Transplant Patients","volume":"17","author":"Kim","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1056\/NEJM199209103271108","article-title":"Acyclovir: A Decade Later","volume":"327","author":"Wood","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/infdis\/157.2.309","article-title":"Acyclovir Prevents Dissemination of Varicella in Immunocompromised Children","volume":"157","author":"Nyerges","year":"1988","journal-title":"J. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0163-4453(93)96648-A","article-title":"Oral acyclovir to prevent dissemination of varicella in immunocompromised children","volume":"26","author":"Meszner","year":"1993","journal-title":"J. Infect."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1183\/09031936.03.00103202","article-title":"Varicella pneumonia in adults","volume":"21","author":"Mohsen","year":"2003","journal-title":"Eur. Respir. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM198306163082404","article-title":"Acyclovir Halts Progression of Herpes Zoster in Immunocompromised Patients","volume":"308","author":"Balfour","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1080\/14787210.2021.1917992","article-title":"Emergence of varicella-zoster virus resistance to acyclovir: Epidemiology, prevention, and treatment","volume":"19","author":"Shiraki","year":"2021","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/cid\/cis879","article-title":"Persistence and antiviral resistance of varicella zoster virus in hematological patients","volume":"56","author":"Vermont","year":"2013","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/QCO.0000000000000288","article-title":"Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: Diagnosis and management","volume":"29","author":"Piret","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1128\/AAC.43.5.1192","article-title":"Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: Results of a multicenter, acyclovir-controlled trial","volume":"43","author":"Lazarus","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1081\/CNV-100000070","article-title":"A Randomized, Double-Blind Trial of Famciclovir Versus Acyclovir for the Treatment of Localized Dermatomal Herpes Zoster in Immunocompromised Patients","volume":"19","author":"Tyring","year":"2001","journal-title":"Cancer Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1159\/000510988","article-title":"Topical Treatment of Acyclovir-Resistant Herpes Simplex Virus Stomatitis after Allogeneic Hematopoietic Cell Transplantation","volume":"43","author":"Heidenreich","year":"2020","journal-title":"Oncol. Res. Treat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jmv.1890460315","article-title":"Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: A randomized double-blind trial","volume":"46","author":"Wutzler","year":"1995","journal-title":"J. Med. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1056\/NEJM199309233291317","article-title":"A New Topical Treatment for Resistant Herpes Simplex Infections","volume":"329","author":"Snoeck","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/tid.12583","article-title":"Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host","volume":"18","author":"Mullane","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jis019","article-title":"ASP2151 for the Treatment of Genital Herpes: A Randomized, Double-Blind, Placebo- and Valacyclovir-Controlled, Dose-Finding Study","volume":"205","author":"Tyring","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1346-8138.13948","article-title":"Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study","volume":"44","author":"Kawashima","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1111\/1346-8138.16027","article-title":"Improvement of acyclovir-resistant herpes zoster infection by amenamevir","volume":"48","author":"Onaka","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.2016.18189","article-title":"Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial","volume":"316","author":"Wald","year":"2016","journal-title":"JAMA."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199403313301304","article-title":"A Randomized Trial of Acyclovir for 7 Days or 21 Days with and without Prednisolone for Treatment of Acute Herpes Zoster","volume":"330","author":"Wood","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J Natl. Compr. Cancer Netw. JNCCN."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/518938","article-title":"Use of Long-Term Suppressive Acyclovir after Hematopoietic Stem-Cell Transplantation: Impact on Herpes Simplex Virus (HSV) Disease and Drug-Resistant HSV Disease","volume":"196","author":"Erard","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2005-09-3624","article-title":"Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation\u2014A randomized double-blind placebo-controlled study","volume":"107","author":"Boeckh","year":"2006","journal-title":"Blood"},{"key":"ref_80","first-page":"574","article-title":"Updated Recommendations for Use of VariZIG\u2014United States, 2013","volume":"62","author":"Marin","year":"2013","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Levin, M.J., Duchon, J.M., Swamy, G.K., and Gershon, A.A. (2019). Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0217749"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Gans, H., and Chemaly, R.F. (2021). Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: A subgroup analysis for safety and outcomes from a large, expanded-access program. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-020-05656-6"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Ike, A.C., Onu, C.J., Ononugbo, C.M., Reward, E.E., and Muo, S.O. (2020). Immune Response to Herpes Simplex Virus Infection and Vaccine Development. Vaccines, 8.","DOI":"10.3390\/vaccines8020302"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-4939-9814-2_2","article-title":"Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology","volume":"Volume 2060","author":"Sandgren","year":"2020","journal-title":"Methods in Molecular Biology"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Chandra, J., Woo, Y., Dutton, J.L., Xu, Y., Li, B., Kinrade, S., Druce, J., Finlayson, N., Griffin, P., and Laing, K.J. (2019). Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I\/IIa trial. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0226320"},{"key":"ref_86","first-page":"754","article-title":"A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2","volume":"217","author":"Burn","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.02745-12","article-title":"An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs","volume":"87","author":"Skoberne","year":"2013","journal-title":"J. Virol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.vaccine.2019.09.090","article-title":"A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2","volume":"38","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"G\u00f6rander, S., Honda-Okubo, Y., B\u00e4ckstr\u00f6m, M., Baldwin, J., Bergstr\u00f6m, T., Petrovsky, N., and Liljeqvist, J.\u00c5. (2021). A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection. Vaccine, Available online: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X21010987.","DOI":"10.1016\/j.vaccine.2021.08.050"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Price, N., and Grose, C. (2021). Corticosteroids Contribute to Serious Adverse Events Following Live Attenuated Varicella Vaccination and Live Attenuated Zoster Vaccination. Vaccines, 9.","DOI":"10.3390\/vaccines9010023"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1016\/j.vaccine.2018.05.078","article-title":"Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection","volume":"36","author":"Alexander","year":"2018","journal-title":"Vaccine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"bcr2015212688","DOI":"10.1136\/bcr-2015-212688","article-title":"Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient","volume":"2016","author":"Costa","year":"2016","journal-title":"BMJ Case Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older","volume":"375","author":"Cunningham","year":"2016","journal-title":"New Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/21645515.2018.1442162","article-title":"Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults","volume":"14","author":"Schwarz","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial","volume":"125","author":"Vink","year":"2019","journal-title":"Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.2020008758","article-title":"Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines","volume":"137","author":"Pleyer","year":"2021","journal-title":"Blood"},{"key":"ref_100","unstructured":"Fink, D.L. (2021, September 15). July 23, 2021 Approval Letter\u2014SHINGRIX. FDA, Available online: https:\/\/www-fda-gov.laneproxy.stanford.edu\/media\/151063\/download."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged \u2265 19 Years: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/14760584.2021.1956906","article-title":"A practitioner\u2019s guide to the recombinant zoster vaccine: Review of national vaccination recommendations","volume":"20","author":"Parikh","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13041-021-00813-7","article-title":"Modeling temperature- and Cav3 subtype-dependent alterations in T-type calcium channel mediated burst firing","volume":"14","author":"Fernandez","year":"2021","journal-title":"Mol. Brain."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"940019","DOI":"10.3389\/fonc.2022.940019","article-title":"Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers","volume":"12","author":"Scanlan","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/2\/439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:24:47Z","timestamp":1760120687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/2\/439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,5]]},"references-count":105,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["v15020439"],"URL":"https:\/\/doi.org\/10.3390\/v15020439","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,5]]}}}